Tropical Journal of Natural Product Research

Available online at https://www.tjnpn.org

Effects of Hydroethanolic Leaf Extract of Ipomoea asarifolia (Convolvulaceae) in Doxorubicin and Isoproterenol-Induced Toxicity in Rats

Abidemi J. Akindele* and Eyitemi L. Palmer

Department of Pharmacology, Therapeutics and Toxicology, Faculty of Basic Medical Sciences, College of Medicine, University of Lagos, Idr-Araba Campus, P.M.B. 12003, Lagos, Nigeria

ARTICLE INFO

Article history:
Received 22 December 2017
Revised 02 February 2018
Accepted 05 February 2018
Published online 07 February 2018

ABSTRACT

This study investigated the effects of the hydroethanolic leaf extract of Ipomoea asarifolia on doxorubicin and isoproterenol-induced toxicities in rats. Rats were randomly assigned into groups- Group 1: distilled water (10 mL/kg orally), Group 2: toxicant, Group 3-5: I. asarifolia (100, 200 and 400 mg/kg orally, respectively) and toxicant, and Group 6: gallic acid (15 mg/kg orally) and toxicant. Treatment lasted for 21 days in the doxorubicin (DOX) model and DOX (5 mg/kg intraperitoneally) was administered on days 7, 14 and 21. Treatment was carried out for 30 days in the isoproterenol (ISO) model and ISO (85 mg/kg subcutaneouusly) was administered on days 28-30. A day after the treatment, blood samples were collected for biochemical analysis and animals were sacrificed. Vital organs were harvested for in-vivo antioxidants assay. In the DOX model, I. asarifolia (100-400 mg/kg) produced significant (p < 0.01) reduction in levels of lactate dehydrogenase (LDH) and triglycerides (TG) relative to the DOX group. The extract reversed the diminution in heart reduced glutathione (GSH) level caused by DOX. ISO significantly increased (p < 0.001) levels of LDH and TG, but these effects were reversed by I. asarifolia (100 and 400 mg/kg). The extract (400 mg/kg) significantly reversed (p < 0.01) the increase in kidney MDA level elicited by ISO. I. asarifolia (200 and 400 mg/kg) significantly (p < 0.001) reversed the increase in liver MDA and reduction in CAT levels elicited by ISO. These findings suggest that the extract possesses cardioprotective effects against doxorubicin and isoproterenol-induced toxicities.

Keywords: Ipomoea asarifolia, Convolvulaceae, Doxorubicin, Isoproterenol, Biochemical parameters, Antioxidant indices.

Introduction

For decades, remedies derived from plants have been used in the prevention, management and treatment of various disease conditions based on their richness in secondary metabolites which are responsible for diverse pharmacological activities. This is the case especially in the rural regions of the world where dwellers have no access to orthodox drugs or cannot afford them. It has been reported that plants have an innate ability to biosynthesize a wide range of non-enzymatic antioxidants capable of attenuating reactive oxygen species (ROS)-induced oxidative damage which has been identified as the root cause of the development and progression of several diseases. Active components of plants have also been harnessed over the past years as new drugs and/or lead compounds. The search for new drugs from plants has been on the increase in recent times based on the need to provide more therapeutic options in the treatment of various diseases. Another germane motivation is the discovery and development of new drugs and standardized phytotherapy with minimal side effects and better efficacy, which are affordable, compared to currently available orthodox drugs.

Doxorubicin (DOX) is an anthracycline glycoside used in cancer therapy. However, its clinical use very often becomes a limiting factor in anticancer therapy due to high irreversible cardiotoxicity. Oxidative stress, lipid peroxidation and mitochondrial dysfunction have been associated with DOX-induced cardiomyopathy. Doxorubicin accumulates mainly in the kidney and to a lesser extent in the liver, heart and small intestine. The drug has been reported to cause various toxicities including cardiac, pulmonary, hepatic, renal, haematological and testicular toxicity, which restricts its chemothapeutic use.

Isoproterenol (ISO) is a catecholamine which is used therapeutically in patients with bradycardia or heart block. Isoproterenol elicits a reduction of total peripheral resistance with simultaneous direct ionotropic and chronotropic effects on the heart; it produces severe stress in the myocardium and myocardial infarction at supra-maximal doses, an effect that results from the generation of highly cytotoxic free radicals (including oxygen free radicals) through the autoxidation of catecholamines. Ipomoea asarifolia (Desr.) Roem. and Schult. (Convolvulaceae), commonly known as “Morning glory”, is widely distributed in West Africa, including Nigeria. In Nigeria, the plant is locally known by diverse names, depending on the part of the country; “Ogho oto ayaba”, “Ewe gboro” (Yoruba, South West-Nigeria) and “Duman kadau” (Hausa, Northern Nigeria). Extracts of the plant have been reported to be used in traditional medicine for the treatment of various ailments, including inflammation and painful conditions. Extracts have been reported to possess antioxidant activity and gastrointestinal disorders and diabetes. Extract of the plant has been reported to possess in-vitro antioxidant activity. As stated earlier, both doxorubicin and isoproterenol-induced toxicity have been linked to free radicals. In view of the foregoing facts, this study was designed to investigate the effect of the hydroethanolic leaf extract of Ipomoea asarifolia in drug (doxorubicin and isoproterenol) induced toxicity in rat.

*Corresponding author. E mail: aakindele@cmul.edu.ng; jakindele@unilag.edu.ng; Tel: +2348072005035; +2348062359726

Citation: Akindele AJ and Palmer EL. Effects of Hydroethanolic Leaf Extract of Ipomoea asarifolia (Convolvulaceae) in Doxorubicin and Isoproterenol-Induced Toxicity in Rats. Trop J Nat Prod Res. 2018; 2(2):59-66. doi.org/10.26538/tjprv/2222

© 2018 Natural Product Research Group, Faculty of Pharmacy, University of Benin. All rights reserved.
Materials and Methods

Chemicals
Doxorubicin (Celon Laboratories Ltd., Andhra Pradesh, India) and isoproterenol (Hristk Chemicals Corp., Mumbai, India). The other chemicals employed for biochemical estimations were of analytical standard grades.

Plant Collection and Identification
Fresh leaves of Ipomoea asarifolia were sourced from Akimborin Village, Afijio Local Government, Oyo State, Nigeria, in the month of April 2013. The plant was identified and authenticated in the Department of Botany and Microbiology, Faculty of Science, University of Lagos, Lagos, Nigeria by Mr. T.K. Odewo. A voucher specimen (LUH 5546) was deposited in the institutional herbarium for reference purpose.

Plant Extraction
The collected plant leaves were washed with distilled water and air-dried until a constant weight was obtained. The dried materials were powdered using an electric blender and extracted (100 g/L) using hydroethanol (1:1). Maceration of the plant material was done 3 times for 48 h each time to ensure exhaustive extraction. The extract was decanted and filtered using Whatman filter paper no. 4 and the combined filtrate was evaporated to dryness under reduced pressure at 40°C. A solid chocolate brown extract was obtained with a yield of 21.21%. The dried extract was reconstituted in distilled water, to obtain desired concentrations, just before administration to experimental animals.

Animals
Adult Swiss mice (15-20 g) and Sprague Dawley rats (150-250 g) of both sexes used for this study were obtained from the Central Animal House, College of Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria. The animals were maintained under standard environmental conditions (23-25°C, 12 h/12 h light/dark cycle) and fed with standard rodent diet (Livestock Feeds Plc., Lagos, Nigeria) and water ad libitum. The rats were housed in polycarbonate cages, grouped into six animals per cage. Animals were acclimatized for 3 weeks before the commencement of the experiment.

The conduct of this study was guided by the provisions of the Experimentation Ethics Committee on Animal Use of the College of Medicine, University of Lagos, Lagos, Nigeria and the United States National Academy of Sciences Guide for the Care and Use of Laboratory Animals.14

Physicochemical Screening
Qualitative physicochemical screening of the hydroethanolic leaf extract of I. asarifolia was carried out using established procedures.15-17

Acute Toxicity Test
Fasted mice (12 h) were allotted to eight groups of five animals each. Six different groups were separately administered I. asarifolia extract (250, 500, 1000, 2000, and 4000 mg/kg) and distilled water (10 mL/kg) given intraperitoneally (i.p.). The 2 remaining groups were independently given I. asarifolia extract (5000 mg/kg) and distilled water orally (p.o.). Mice were observed for 2 h post-treatment for behavioural changes. Twenty-four hours post-administration, mortality in each group was noted, as applicable, and the median lethal dose (LD50) was derived using the log dose-probit analysis method.18 Mice that survived in each group were further observed for 14 days for possible signs of delayed toxicity.

Experimental Protocol
A total of 72 rats were divided into 2 pools of 36 rats each for each of the two models employed in this study. For each model, 36 rats were divided into 6 groups consisting of 6 rats each. The ratio of male: female rats was equal across the different groups.

Doxorubicin-Induced Toxicity Model

Group 1: Distilled water 10 mL/kg p.o. (control)
Group 2: DOX
Group 3: I. asarifolia extract 100 mg/kg + DOX
Group 4: I. asarifolia extract 200 mg/kg + DOX
Group 5: I. asarifolia extract 400 mg/kg + DOX
Group 6: Gallic acid 15 mg/kg + DOX

DOX was administered at a dose of 5 mg/kg i.p. on the 7th, 14th and 21st days making a cumulative dose of 15 mg/kg.1 I. asarifolia extract and gallic acid were given p.o. for 21 days. Rats were weighed before the commencement of treatment and at 7 days intervals throughout the course of the experiment. Twenty-four hours after the last treatment, rats were anaesthetized by i.p. administration of 5 mL/kg of a solution of 1% chloralose in 25% urethane (w/v) and blood samples were collected into plain sample bottles through the retro-orbital plexus vein. Thereafter, rats were sacrificed by cervical dislocation. The heart, liver and kidneys were harvested from each rat and weigh. These vital organs, rinsed in phosphate buffered saline, were used for estimation of antioxidant indices.

Isoproterenol-Induced Toxicity Model
The grouping was the same as in the doxorubicin-induced toxicity model, except that I. asarifolia extract and gallic acid were administered p.o. for 30 days, and ISO was given subcutaneously (s.c.) at the dose of 85 mg/kg on the 29th and 30th day in place of DOX. Twelve hours after the second injection of ISO, procedures carried out in the doxorubicin-induced toxicity model were repeated.

Biochemical Parameters
Blood samples collected into plain sample bottles were allowed to coagulate. Serum was collected after centrifugation at 3000 rpm for 5 min. for estimation of biochemical parameters, including lactate dehydrogenase (LDH), triglycerides (TG), high-density lipoprotein (HDL), creatinine, and urea using Roche and Cobas commercial kits and the Roche Hitachi automated 912 analyser.20

Antioxidant Indices
The supernatants derived from the homogenates of the isolated heart, liver and kidney tissues were used for the estimation of antioxidant indices, including malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), reduced glutathione (GSH), and glutathione peroxidase (GPx), using established procedures.20,21

Statistical Analysis
Results obtained in this study are expressed as mean ± S.E.M. The data were analyzed using One-way analysis of variance (ANOVA) with Tukey’s post-hoc test using GraphPad Prism 6 Software (GraphPad Software Inc., CA, USA). Results were considered significant at p < 0.05.

Results and Discussion

As shown in Table 1, DOX caused significant increase (p < 0.001) in the level of LDH compared with control. The DOX-induced increase in LDH was significantly reversed (p < 0.001) by I. asarifolia (200 and 400 mg/kg) and gallic acid (15 mg/kg), with I. asarifolia at the dose of 200 mg/kg producing the greatest reversal. DOX caused significant increase in the levels of creatinine (p < 0.01) and urea (p < 0.01) relative to control.

Values for creatinine in I. asarifolia intervention groups (100, 200 and 400 mg/kg) were comparable and not significantly different from that of DOX (p > 0.05) while gallic acid (15 mg/kg) caused significant reduction (p < 0.01) in the level of creatinine compared with the DOX group. Significant elevation (p < 0.01, 0.001) in the level of urea was observed in the DOX and I. asarifolia 200 and 400 mg/kg intervention groups compared with control while values in the I. asarifolia 100 mg/kg and gallic acid 15 mg/kg were comparable and not significantly different (p > 0.05) from control (Table 1). DOX elicited significant reduction (p < 0.001) in the level of HDL relative to control. The same trend of the result (significant reduction in the level of HDL) was observed in the I. asarifolia (100, 200 and 400 mg/kg) and gallic acid (15 mg/kg) intervention groups in respect of TG, DOX caused significant increase (p < 0.001) in the level of this parameter. I. asarifolia interventions (100, 200 and 400 mg/kg) significantly reversed (p < 0.001) the effect of DOX on TG with the greatest reversal elicited at the dose of 100 mg/kg. Gallic acid did not significantly alter (p > 0.05) the effect of DOX on the level of TG (Table 1).

It has been reported that doxorubicin-induced free radical generation triggers membrane degradation and disruption of cardiac myocytes which can lead to elevations of LDH.22,23 The results obtained in this study showed an increase in levels of LDH when doxorubicin was administered alone to rats compared with control. This indicates cardiotoxicity which may be as a result of generation of free radicals which extensively damages the myocardium. This damage results in increased membrane permeability thereby leading to leakage of LDH25 and increased serum concentration. During cardiototoxicity, there is interference in the metabolism and biosynthesis of lipids thereby increasing TG levels and decreasing the levels of HDL in the serum.25 In this study, doxorubicin...
administered alone to rats elicited a significant increase in TG and reduction in HDL levels in the serum compared with control, indicating cardiotoxicity. The ameliorative effect of the hydroethanolic leaf extract of *I. asarifolia* was observed at doses of 100, 200 and 400 mg/kg based on observed significant reduction in the levels of LDH and TG relative to the doxorubicin 15 mg/kg group. This suggests that the extract possesses cardioprotective activity. In this study, doxorubicin also caused significant increases in the levels of creatinine and urea compared to the control group. Elevations in the serum levels of urea and creatinine are indicative of renalotoxicity.29 This confirms the ability of doxorubicin to cause toxicity in respect of the kidneys. The increase in the serum levels of urea and creatinine was not reversed by co-administration of the extract at various doses and gallic acid with doxorubicin. As shown in Table 2, ISO significantly increased (p < 0.001) the level of LDH relative to control, with *I. asarifolia* at the dose of 200 mg/kg and gallic acid (15 mg/kg) not reversing this effect (p > 0.05). However, *I. asarifolia* interventions at doses of 100 and 400 mg/kg significantly reversed (p < 0.001) the elevation in the level of LDH caused by ISO. Also, ISO and the various interventions (*I. asarifolia* 100, 200 and 400 mg/kg, and gallic acid 15 mg/kg) did not generally cause significant alteration (p > 0.05) in the levels of creatinine and urea compared with control and ISO (Table 2). ISO caused a significant reduction (p < 0.05) in the level of HDL compared with the control group. This effect of ISO was not reversed by the various interventions (*I. asarifolia* 100, 200 and 400 mg/kg, and gallic acid 15 mg/kg). ISO significantly increased (p < 0.001) the level of TG relative to the control group. This effect of ISO was significantly reversed *I. asarifolia* 100 and 400 mg/kg (p < 0.001) and gallic acid (15 mg/kg) (p < 0.01) (Table 2). In this study, significant increases in the levels of LDH and TG, and significant reduction in the level of HDL were observed with the administration of isoproterenol alone to rats compared with control. This agrees with previous research findings where significant increases in LDH and TG, and significant reduction in HDL levels were observed in the serum of isoproterenol-treated rats.32,33 *I. asarifolia* exhibited ameliorative effect on isoproterenol-induced cardiac dysfunctions at 200 and 400 mg/kg co-administered on cardiac parameters. This shows significant reductions in the levels of LDH and TG relative to the toxicant group. Isoproterenol showed no tendency to cause renotoxicity as the levels of urea and creatinine were not significantly altered relative to the control group. The extract at various doses and gallic acid co-administered with isoproterenol did not significantly alter urea and creatinine levels compared to the control and toxicant groups. Gallic acid (3,4,5 trihydrobenzoic acid) is a phenolic substance with documented antioxidant and hepatoprotective properties.29 It has also been reported to have antioxidative and anticarcinogenic properties; it inhibits lipid peroxidation, reduces oxidative stress and scavenges free radicals produced in oxidative stress condition.34 In respect of serum biochemical parameters, gallic acid significantly reduced the levels of LDH and creatinine relative to the DOX group. Also, it significantly reduced the levels of TG compared with the ISO group. These observations suggest cardio- and renoprotective effects for gallic acid. As shown in Table 3, DOX caused significant reduction in the heart level of GSH (p < 0.001), CAT (p < 0.01) and GPx (p < 0.05), and non-significant reduction in the level of SOD. The effect of DOX on GSH was significantly reduced by *I. asarifolia* 200 mg/kg and gallic acid 15 mg/kg (p < 0.01). Only gallic acid 15 mg/kg significantly reversed the effect of DOX on SOD, CAT and GPx (p < 0.05, 0.01 and 0.05 respectively). DOX significantly reduced the level of MDA (p < 0.01) compared to control with *I. asarifolia* 400 mg/kg and gallic acid 15 mg/kg eliciting significant reversals (p < 0.05, 0.01 respectively). Oxidative stress is a pathologic condition resulting from either increased production of free radicals or decreased levels of antioxidants like GSH, CAT, GPx, and SOD.35 Malondialdehyde, end-product of lipid peroxidation, is further elevated by overproduction of free radicals which in turn reduces the antioxidants enzymes and increases disturbance of calcium influx induced by toxic agents.3 In this study, doxorubicin significantly reduced heart levels GSH, CAT and GPx relative to control, thereby indicating cardiotoxicity. This is in accordance with previous research findings by Saad et al.36 that documented decreases in GSH, GPx and CAT levels. Doxorubicin is enzymatically converted to a semiquinone radical which directly reduces the antioxidants like GSH and CAT and forms a toxic substance, superoxide radicals, namely superoxide and hydrogen peroxide.31 The ameliorative effect of the extract in reversing the cardiotoxicity associated with the use of doxorubicin is indicated by the fact that the extract at the dose of 200 mg/kg significantly increased the level of GSH relative to the toxicant group. Also, the administration of the standard drug (gallic acid) in combination with doxorubicin confirmed the antioxidant potential of the drug in ameliorating the cardiotoxic effect of doxorubicin as justified by significant increases in the level of GSH, SOD, CAT and GPx compared with the doxorubicin only group. In respect of the heart, as shown in Table 4, ISO caused a significant increase in the level of GSH. SOD, CAT and GPx (p < 0.05, 0.001 and 0.001 respectively) the various interventions (*I. asarifolia* 100, 200 and 400 mg/kg, and gallic acid 15 mg/kg) did not significantly alter the effects of ISO on these in-vivo antioxidants. No significant change in the level of MDA was observed in all the treatment groups relative to control or the ISO group. Isoproterenol has been reported to cause severe oxidative stress in the myocardium.36 In this study, isoproterenol significantly reduced the heart levels of all four antioxidants (GSH, CAT, GPx and SOD) with a doxorubicin non-significant increase in the level of MDA compared with control. This observation is in accordance with previous research reports that documented significant increases in the levels of diagnostic marker enzymes in the plasma and a decline in antioxidants, including GSH, following injections of isoproterenol.37 However, the extract at various doses and gallic acid co-administered with isoproterenol did not reverse the effects of ISO on antioxidant parameters in the heart. This suggests that the cardioprotective effect of the extract as deduced from the results of the biochemical parameters assay, in respect of the ISO model, is not associated with antioxidant activity in the heart. As shown in Table 5, DOX did not cause significant change (p > 0.05) in the kidney level of all the antioxidant indices relative to the control group. Compared to the control and DOX groups, *I. asarifolia* 100 mg/kg caused significant increase in the level of CAT (p < 0.001, 0.01 respectively). In group treated with isoproterenol, the kidney level of CAT did not significantly increase while the effects of ISO and the interventions *I. asarifolia* 200 mg/kg and gallic acid 15 mg/kg did not significantly reverse the effects of ISO on these in-vivo antioxidants and MDA compared with the control group. However, the extract at doses of 100 and 400 mg/kg co-administered with the toxican increased the levels of CAT, SOD and GPx relative to the doxorubicin group. This possibly suggests a tendency to increase renal in vivo antioxidant activity in pathologic conditions. In respect of the kidneys, relative to the control group, ISO did not cause significant reductions in the levels of SOD, CAT and GPx. However, ISO significantly reduced the levels of SOD, CAT and GPx, and significantly increased (p < 0.05) the level of MDA compared with the control group. Only gallic acid 15 mg/kg significantly reversed (p < 0.01, 0.001) the effect of ISO on SOD and GPx. However, *I. asarifolia* 400 mg/kg caused significantly reduction (p<0.05) in the levels of MDA relative to the ISO group (Table 6). Concerning isoproterenol-induced toxicity, the toxicant significantly reduced the kidney levels SOD and GPx, and concurrently significantly increased the level of MDA relative to the control group. *I. asarifolia* at the dose of 400 mg/kg reversed the effect of isoproterenol on MDA while gallic acid acted likewise in respect of SOD and GPx. Conservatively, these results suggest some beneficial effect for gallic acid and the extract at 400 mg/kg against pro-oxidative tendencies in the kidney. In respect of the liver, as shown in Table 7, DOX did not elicit any significant change (p > 0.05) in the level of all the antioxidant indices compared with the control group. *I. asarifolia* 100 mg/kg and gallic acid 15 mg/kg caused significant reduction in the levels of GSH (p < 0.05, 0.01) relative to the control and DOX groups. *I. asarifolia* 200 and 400 mg/kg, and gallic acid 15 mg/kg caused significant reduction in the level of SOD and GPx (p < 0.05, 0.01) relative to the DOX group. A significant increase (p < 0.05) was elicited by gallic acid in respect of the effect of ISO on SOD and GPx as compared with the DOX group. Concerning the liver, doxorubicin did not significantly alter the levels of antioxidant indices relative to the control group. Compared to the toxicant group, *I. asarifolia* at various doses and gallic acid did not beneficially change the values of the antioxidant indices. Unlike the case with doxorubicin, isoproterenol caused significant diminution in the levels of SOD, CAT and GPx, with accompanying increase in the level of MDA. The extract at 200 and 400 mg/kg respectively elicited beneficial effects in reducing the levels of MDA in decreasing the level of CAT relative to the toxicant group. In respect of the liver, ISO significantly reduced the levels of SOD, CAT and GPx (p<0.01, 0.05 and 0.01 respectively) relative to the control. ISO also significantly increased (p<0.001) the level of MDA. *I. asarifolia* 200 and 400 mg/kg significantly reversed the effects of ISO on MDA and SOD. However, the extract did not significantly affect the levels of GSH and CAT, and the levels of GPx were not significantly affected (p > 0.05) with the administration of *I. asarifolia* at 200 and 400 mg/kg, and gallic acid 15 mg/kg. This suggests that ISO-induced oxidative stress in the liver. The reversal of the effects of ISO on hepatic levels of MDA and CAT by the extract is suggestive of potential ameliorative effect on hepatotoxicity.
### Table 1: Effect of *I. asarifolia* extract on biochemical parameters in doxorubicin-induced toxicity test.

| Treatment group           | Dose (mg/kg) | LDH (IU/L) | Creatinine (mg/dL) | Urea (mg/dL) | HDL (mg/dL) | TG (mg/dL) |
|---------------------------|--------------|------------|--------------------|--------------|--------------|------------|
| Distilled water           | 10 (ml/kg)   | 1685.26 ± 9.71 | 43.98 ± 0.44 | 5.38 ± 0.14 | 1.66 ± 0.03 | 0.57 ± 0.02 |
| DOX                       | 5            | 1983.08 ± 15.81 | 54.35 ± 0.16a | 7.68 ± 0.20b | 1.28 ± 0.03b | 1.49 ± 0.03c |
| DOX + *I. asarifolia*     | 5/100        | 2065.56 ± 60.33 | 51.05 ± 0.60 | 6.70 ± 0.07 | 1.02 ± 0.10c | 0.85 ± 0.02a |
| DOX + *I. asarifolia*     | 5/200        | 1035.43 ± 35.58b | 52.82 ± 3.37 | 8.08 ± 0.46b | 1.23 ± 0.03b | 1.24 ± 0.02a |
| DOX + *I. asarifolia*     | 5/400        | 1185.98 ± 19.50a | 51.53 ± 3.07 | 7.50 ± 0.80b | 1.28 ± 0.03b | 0.88 ± 0.05a |
| DOX + Gallic acid         | 5/15         | 1620.02 ± 53.93 | 45.56 ± 0.37 | 6.74 ± 0.02 | 1.40 ± 0.03a | 1.39 ± 0.02** |
| *I. asarifolia*           | 400          | 1786.30 ± 212.54 | 54.71 ± 3.36b | 6.24 ± 0.43 | 1.32 ± 0.08b | 0.80 ± 0.05c |

Values are mean ± S.E.M. (n = 3-5), *p < 0.05, **p < 0.01, ***p < 0.001 vs. distilled water; *p < 0.05 vs. DOX; *p < 0.01 vs. DOX + *I. asarifolia* 400 mg/kg (one-way ANOVA with Tukey’s post-hoc test).

### Table 2: Effect of *I. asarifolia* extract on biochemical parameters in isoproterenol-induced toxicity test.

| Treatment group           | Dose (mg/dL) | LDH (IU/L) | Creatinine (mg/dL) | Urea (mg/dL) | HDL (mg/dL) | TG (mg/dL) |
|---------------------------|--------------|------------|--------------------|--------------|--------------|------------|
| Distilled water           | 10 (ml/kg)   | 1685.26 ± 30.16 | 43.98 ± 2.19 | 5.38 ± 0.35 | 1.66 ± 0.08 | 0.57 ± 0.01 |
| ISO                       | 85           | 2440.58 ± 3.00b | 46.26 ± 3.54 | 5.95 ± 0.79 | 1.18 ± 0.08a | 0.67 ± 0.01c |
| ISO + *I. asarifolia*     | 85/100       | 1690.58 ± 32.27b | 46.03 ± 6.07 | 7.08 ± 2.05 | 1.18 ± 0.09a | 0.56 ± 0.01b |
| ISO + *I. asarifolia*     | 85/200       | 2353.00 ± 7.22b | 45.84 ± 3.33 | 6.60 ± 0.29 | 1.10 ± 0.00a | 0.70 ± 0.01c |
| ISO + *I. asarifolia*     | 85/400       | 1910.95 ± 33.22b | 43.67 ± 2.77 | 4.83 ± 0.30 | 1.18 ± 0.14a | 0.57 ± 0.01b |
| ISO + Gallic acid         | 85/15        | 2464.74±104.41*** | 47.98 ± 3.35 | 6.16 ± 0.29 | 1.30 ± 0.11 | 0.62 ± 0.00** |
| *I. asarifolia*           | 400          | 2049.94 ± 170.38 | 56.37 ± 3.74 | 6.44 ± 0.87 | 1.60 ± 0.09 | 0.82±0.02*** |

Values are mean ± S.E.M. (n = 3-5), *p < 0.05, **p < 0.01, ***p < 0.001 vs. distilled water; *p < 0.05, **p < 0.01, ***p < 0.001 vs. ISO; *p < 0.05, **p < 0.01, ***p < 0.001 vs. ISO + *I. asarifolia* 400 mg/kg (one-way ANOVA with Tukey’s post-hoc test).

### Table 3: Effect of *I. asarifolia* extract on heart antioxidant indices in doxorubicin-induced toxicity test.

| Treatment group           | Dose (mg/kg) | GSH (U/mg protein) | SOD (U/mg protein) | CAT (U/mg protein) | GPx (U/mg protein) | MDA (U/mg protein) |
|---------------------------|--------------|--------------------|-------------------|-------------------|-------------------|-------------------|
| Distilled water           | 10 (ml/kg)   | 0.48 ± 0.03        | 4.47 ± 0.39       | 31.24 ± 0.82      | 1.36 ± 0.12       | 0.11 ± 0.01       |
| DOX                       | 5            | 0.06 ±0.01c        | 3.15 ±0.21a       | 19.19±1.38b       | 0.95 ± 0.06c      | 0.06 ± 0.00b      |
| DOX + *I. asarifolia*     | 5/100        | 0.15 ±0.02c        | 3.71 ± 0.06       | 21.29 ±0.19a      | 1.12 ± 0.02       | 0.08 ± 0.01       |
| DOX + *I. asarifolia*     | 5/200        | 0.26 ±0.06**       | 2.43 ± 0.19c      | 20.82 ± 1.54b     | 0.73 ± 0.06c      | 0.08 ± 0.01       |
| DOX + *I. asarifolia*     | 5/400        | 0.11 ±0.01c        | 3.11 ± 0.45a      | 25.18 ± 2.86c     | 0.94 ± 0.14a      | 0.10 ± 0.01b      |
| DOX + Gallic acid         | 5/15         | 0.24 ±0.025a       | 4.67 ± 0.36c**    | 33.13 ± 3.12c     | 1.41 ± 0.11**     | 0.12 ± 0.01b      |
| *I. asarifolia*           | 400          | 0.30 ± 0.09b       | 5.01 ± 0.17a**    | 32.36 ± 0.95c     | 1.51 ± 0.05b**    | 0.11 ± 0.01b      |

Values are mean ± S.E.M. (n = 5), *p < 0.05, **p < 0.01, ***p < 0.001 vs. distilled water; *p < 0.05, **p < 0.01, ***p < 0.001 vs. DOX; *p < 0.05, **p < 0.01, ***p < 0.001 vs. DOX + *I. asarifolia* 400 mg/kg (one-way ANOVA with Tukey’s post-hoc test).
Table 4: Effect of *I. asarifolia* extract on heart antioxidant indices in isoproterenol-induced toxicity test.

| Treatment group       | Dose (mg/kg) | GSH (U/mg protein) | SOD (U/mg protein) | CAT (U/mg protein) | GPx (U/mg protein) | MDA (U/mg protein) |
|-----------------------|--------------|--------------------|--------------------|--------------------|--------------------|-------------------|
| Distilled water       | 10 (mL/kg)   | 0.48 ± 0.03        | 4.47 ± 0.39        | 31.24 ± 0.82       | 1.36 ± 0.12        | 0.11 ± 0.01       |
| ISO                   | 85           | 0.28 ± 0.04        | 1.88 ± 0.15        | 22.56 ± 1.42       | 0.57 ± 0.04        | 0.20 ± 0.03       |
| ISO + *I. asarifolia* | 85/100       | 0.37 ± 0.07        | 2.26 ± 0.21        | 26.08 ± 1.86       | 0.68 ± 0.07        | 0.22 ± 0.06       |
| ISO + *I. asarifolia* | 85/200       | 0.16 ± 0.01        | 1.67 ± 0.08        | 15.20 ± 0.83       | 0.50 ± 0.02        | 0.12 ± 0.00       |
| ISO + *I. asarifolia* | 85/400       | 0.21 ± 0.02        | 1.95 ± 0.15        | 16.86 ± 0.55       | 0.58 ± 0.00        | 0.10 ± 0.02       |
| ISO + Gallic acid     | 85/15        | 0.36 ± 0.05        | 2.14 ± 0.27        | 22.16 ± 3.16       | 0.65 ± 0.08        | 0.16 ± 0.05       |
| *I. asarifolia*       | 400          | 0.27 ± 0.04        | 2.22 ± 0.17        | 16.55 ± 1.03       | 0.68 ± 0.05        | 0.09 ± 0.01       |

Values are mean ± S.E.M. (n = 5). *p < 0.05, *p < 0.01, *p < 0.001 vs. distilled water; *p < 0.05 vs. ISO (One-way ANOVA with Tukey’s post-hoc test).

Table 5: Effect of *I. asarifolia* hydroethanolic leaf extract on kidney antioxidant indices in doxorubicin-induced toxicity test.

| Treatment Group       | Dose (mg/kg) | GSH (U/mg protein) | SOD (U/mg protein) | CAT (U/mg protein) | GPx (U/mg protein) | MDA (U/mg protein) |
|-----------------------|--------------|--------------------|--------------------|--------------------|--------------------|-------------------|
| Distilled water       | 10 (mL/kg)   | 0.24 ± 0.00        | 3.05 ± 0.07        | 18.35 ± 1.13       | 2.15 ± 0.02        | 0.11 ± 0.01       |
| DOX                   | 5            | 0.25 ± 0.02        | 4.38 ± 0.38        | 20.82 ± 1.81       | 1.29 ± 0.11        | 0.12 ± 0.03       |
| DOX + *I. asarifolia* | 5/100        | 0.32 ± 0.05        | 5.86 ± 0.68        | 34.13 ± 3.49       | 1.73 ± 0.20        | 0.19 ± 0.05       |
| DOX + *I. asarifolia* | 5/200        | 0.27 ± 0.03        | 3.17 ± 0.17        | 20.98 ± 0.27       | 0.95 ± 0.05        | 0.12 ± 0.01       |
| DOX + *I. asarifolia* | 5/400        | 0.14 ± 0.02        | 1.76 ± 0.06        | 16.20 ± 0.38       | 0.53 ± 0.02        | 0.09 ± 0.00       |
| DOX + Gallic acid     | 5/15         | 0.35 ± 0.06        | 3.58 ± 0.63        | 23.22 ± 3.06       | 1.06 ± 0.18        | 0.14 ± 0.05       |
| *I. asarifolia*       | 400          | 0.44 ± 0.06        | 4.79 ± 0.34        | 31.73 ± 2.16       | 1.45 ± 0.10        | 0.11 ± 0.02       |

Values are mean ± S.E.M. (n = 5). *p < 0.05, *p < 0.01, *p < 0.001 vs. distilled water; *p < 0.05, *p < 0.01 vs. DOX; *p < 0.05, **p < 0.001 vs. DOX + *I. asarifolia* 400 mg/kg (one-way ANOVA with Tukey’s post-hoc test).

Table 6: Effect of *I. asarifolia* hydroethanolic leaf extract on kidney antioxidant indices in isoproterenol-induced toxicity test.

| Treatment group       | Dose (mg/kg) | GSH (U/mg protein) | SOD (U/mg protein) | CAT (U/mg protein) | GPx (U/mg protein) | MDA (U/mg protein) |
|-----------------------|--------------|--------------------|--------------------|--------------------|--------------------|-------------------|
| Distilled water       | 10 (mL/kg)   | 0.24 ± 0.00        | 3.05 ± 0.07        | 18.35 ± 1.13       | 0.90 ± 0.02        | 0.11 ± 0.01       |
| ISO                   | 85           | 0.18 ± 0.01        | 1.39 ± 0.20        | 20.05 ± 2.26       | 0.41 ± 0.06        | 0.23 ± 0.04       |
| ISO + *I. asarifolia* | 85/100       | 0.26 ± 0.06        | 1.48 ± 0.08        | 19.39 ± 1.44       | 0.40 ± 0.03        | 0.29 ± 0.03       |
| ISO + *I. asarifolia* | 85/200       | 0.24 ± 0.02        | 1.41 ± 0.05        | 15.20 ± 0.05       | 0.42 ± 0.01        | 0.19 ± 0.00       |
| ISO + *I. asarifolia* | 85/400       | 0.22 ± 0.01        | 1.39 ± 0.18        | 12.41 ± 0.13       | 0.42 ± 0.05        | 0.11 ± 0.03       |
| ISO + Gallic acid     | 85/15        | 0.24 ± 0.02        | 2.46 ± 0.27        | 15.27 ± 1.03       | 0.73 ± 0.08        | 0.18 ± 0.02       |
| *I. asarifolia*       | 400          | 0.20 ± 0.04        | 1.29 ± 0.19        | 14.05 ± 0.87       | 0.38 ± 0.06        | 0.16 ± 0.03       |

Values are mean ± S.E.M. (n = 5). *p < 0.05, *p < 0.001 vs. distilled water; *p < 0.01 vs. ISO; *p < 0.01 vs. ISO + *I. asarifolia* 400 mg/kg (one-way ANOVA with Tukey’s post-hoc test).
nd 4000 mg/kg. The extract of *I. asarifolia* 400 mg/kg, at the dose of 5000 mg/kg (one-way ANOVA with Tukey’s post-hoc test). Gallic acid intervention in ISO-treated rats caused significant increase (p < 0.05) in change in body weight of rats on day 21 compared to the control and ISO groups. On day 14, gallic acid intervention in ISO-treated rats also caused a significant increase (p < 0.05) in change in body weight of rats compared to the control group, with no significant difference (p > 0.05) relative to the ISO group. Gallic acid treatment in *I. asarifolia* extract 100 mg/kg intervention in ISO-treated rats also caused a significant increase (p < 0.05) in change in body weight of rats on day 21 compared to the control and ISO groups. *I. asarifolia* extract 100 mg/kg intervention in ISO-treated rats also caused a significant increase (p < 0.05) in change in body weight of rats compared to the control group at this interval, with value being comparable and not significantly different (p > 0.05) relative to the control group, ISO, and gallic acid treated groups with the control and ISO groups. On day 14, > 0.05) in change in body weight of rats compared to the control group, ISO, and gallic acid treated groups with the control and ISO groups.

As shown in Figure 1, there were no significant differences (p > 0.05) in the change in body weight of rats across the treatment groups on days 7, 14 and 21 compared to the control group in the DOX model. In respect of the ISO model, on days 7 and 28 there were no significant differences (p > 0.05) in change in body weight of rats comparing *I. asarifolia* extract and gallic acid treated groups with the control and ISO groups. On day 14, gallic acid intervention in ISO-treated rats also caused a significant increase (p < 0.05, 0.01) in change in body weight of rats compared to the control group, with no significant difference (p > 0.05) relative to the ISO group. Gallic acid treatment in *I. asarifolia* extract 100 mg/kg intervention in ISO-treated rats also caused a significant increase (p < 0.05) in change in body weight of rats on day 21 compared to the control and ISO groups. *I. asarifolia* extract 100 mg/kg intervention in ISO-treated rats also caused a significant increase (p < 0.05) in change in body weight of rats compared to the control group at this interval, with value being comparable and not significantly different (p > 0.05) relative to the control group. The combination with the extract at various doses presented a similar trend of result while the ISO plus gallic acid group showed a significant increase in change in weight gain from mid to the end of the treatment period. *I. asarifolia* extract did not produce any mortality when administered p.o. at the dose of 5000 mg/kg. In respect of the i.p. route, mortality was 0 and 100% respectively at doses of 250 and 4000 mg/kg. The i.p. LDso value was obtained to be 1000 mg/kg with a confidence interval of 482.68-1517.32 mg/kg. It has been documented that no dose-related toxicity was observed above 5000 mg/kg body weight. Hence, the hydroethanolic leaf extract of *I. asarifolia* can be considered relatively non-toxic. The results of the oral acute toxicity test and the i.p. LDso value corresponds to what was reported by Akindele et al.

Phytochemicals are a large group of plant-derived compounds hypothesized to be responsible for much of the disease protection conferred from diets high in fruits, vegetables, beans, cereals, and plant-based beverages such as tea and wine. Phytochemical screening of the

---

### Table 7: Effect of *I. asarifolia* hydroethanolic leaf extract on liver antioxidant indices in doxorubicin-induced toxicity test.

| Treatment group     | Dose (mg/kg) | GSH (U/mg protein) | SOD (U/mg protein) | CAT (U/mg protein) | GPx (U/mg protein) | MDA (U/mg protein) |
|---------------------|--------------|--------------------|--------------------|--------------------|-------------------|-------------------|
| Distilled water     | 10 (ml/kg)   | 0.28 ± 0.03        | 3.67 ± 0.38        | 19.90 ± 1.78       | 1.09 ± 0.12       | 0.08 ± 0.01       |
| DOX                 | 5            | 0.27 ± 0.03        | 4.66 ± 0.11        | 17.75 ± 0.68       | 1.41 ± 0.03       | 0.05 ± 0.00       |
| DOX + *I. asarifolia* 5/100 | 0.13 ± 0.01 <b>**</b> | 3.56 ± 0.41        | 15.79 ± 0.51       | 1.08 ± 0.13       | 0.08 ± 0.00       |
| DOX + *I. asarifolia* 5/200 | 0.20 ± 0.05  | 3.28 ± 0.32         | 15.89 ± 1.18       | 0.984 ± 0.10       | 0.08 ± 0.01       |
| DOX + *I. asarifolia* 5/400 | 0.17 ± 0.02  | 2.72 ± 0.10         | 19.89 ± 1.75       | 0.81 ± 0.03       | 0.08 ± 0.01       |
| DOX + Gallic acid 5/15 | 0.10 ± 0.01     | 2.92 ± 0.29        | 18.57 ± 3.52       | 0.86 ± 0.08       | 0.09 ± 0.02       |
| *I. asarifolia* 400 | 0.15 ± 0.01   | 3.06 ± 0.06         | 16.46 ± 0.18       | 0.91 ± 0.02       | 0.08 ± 0.01       |

Values are mean ± S.E.M. (n = 5). *p < 0.05, **p < 0.01 vs. distilled water; *p < 0.05, **p < 0.01 vs. DOX (one-way ANOVA with Tukey’s post-hoc test).

---

### Table 8: Effect of *I. asarifolia* hydroethanolic leaf extract on liver antioxidant indices in isoproterenol-induced toxicity test.

| Treatment group     | Dose (mg/kg) | GSH (U/mg protein) | SOD (U/mg protein) | CAT (U/mg protein) | GPx (U/mg protein) | MDA (U/mg protein) |
|---------------------|--------------|--------------------|--------------------|--------------------|-------------------|-------------------|
| Distilled water     | 10 (ml/kg)   | 0.28 ± 0.02        | 3.67 ± 0.38        | 19.90 ± 1.78       | 1.09 ± 0.12       | 0.08 ± 0.01       |
| ISO                 | 85           | 0.21 ± 0.01        | 2.29 ± 0.03        | 12.73 ± 0.92       | 0.67 ± 0.01       | 0.23 ± 0.03       |
| ISO + *I. asarifolia* 85/100 | 0.30 ± 0.03  | 2.25 ± 0.06         | 14.70 ± 1.18       | 0.66 ± 0.03       | 0.24 ± 0.01       |
| ISO + *I. asarifolia* 85/200 | 0.19 ± 0.01  | 1.37 ± 0.08         | 13.17 ± 0.60       | 0.41 ± 0.02       | 0.06 ± 0.00       |
| ISO + *I. asarifolia* 85/400 | 0.25 ± 0.03  | 2.28 ± 0.27         | 22.27 ± 2.56       | 0.69 ± 0.08       | 0.19 ± 0.05       |
| ISO + Gallic acid 85/15 | 0.24 ± 0.01  | 1.86 ± 0.35         | 13.81 ± 0.84***    | 0.56 ± 0.11       | 0.14 ± 0.01       |
| *I. asarifolia* 400 | 0.18 ± 0.01  | 1.16 ± 0.16**<b>***</b> | 10.54 ± 0.38***<b>***</b> | 0.35 ± 0.05**<b>***</b> | 0.08 ± 0.01**<b>***</b> |

Values are mean ± S.E.M. (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001 vs. distilled water; *p < 0.05, **p < 0.01, ***p < 0.001 vs. ISO; *p < 0.05, **p < 0.01 vs. ISO + *I. asarifolia* 400 mg/kg (one-way ANOVA with Tukey’s post-hoc test).

---

**Figure 1:** Effect of *I. asarifolia* extract on change in body weight in doxorubicin-induced toxicity test. Bars are mean ± S.E.M. (n=3-5). p > 0.05 (one-way ANOVA with Tukey’s post-hoc test).

**Figure 2:** Effect of *I. asarifolia* extract on change in body weight in isoproterenol-induced toxicity test. Bars are mean ± S.E.M. (n=3-5). *p < 0.05, **p < 0.01 vs. distilled water; *p < 0.001 vs. DOX (one-way ANOVA with Tukey’s post-hoc test).
hydroethanolic leaf extract of *I. asarifolia* revealed the presence of saponins, tannins, flavonoids, phenols, reducing sugars, glycosides, terpenoids, steroids and phlobatannins. Flavonoids and tannins are well known polyphenolic natural antioxidants. Phenols have been found to be very effective in preventing the build-up of damaging cholesterol.  

**Conclusion**

The results obtained in this study suggest that the hydroethanolic leaf extract of *Ipomoea asarifolia* possesses cardioprotective effects against doxorubicin and isoproterenol induced toxicities. The effect of the extract in respect of the DOX model is associated with enhancement of GSH levels. The extract also reduced the extent of lipid peroxidation induced by ISO in the kidneys and liver by enrichment of CAT level.

**Conflict of interest**

The authors declare no conflict of interest.

**Authors’ Declaration**

The authors hereby declare that the work presented in this article is original and that any liability for claims relating to the content of this article will be borne by them.

**Acknowledgements**

The authors wish to acknowledge the technical support rendered by Mr. C.M. Chijioke (Department of Pharmacology, Therapeutics & Toxicology) and Mr. S. Adenekan (Department of Biochemistry) of the Faculty of Basic Medical Sciences, College of Medicine, University of Lagos, Lagos, Nigeria.

**References**

1. Oseghale IO, Isemeje VO, Erharuyi O, Iheanacho C, Falodun A. A review of the phytochemistry and pharmacology of *Elesine coracana* (Linn) Poocae: A popular Nigerian edible grain. Trop J Nat Prod Res. 2017; 1(6):227-235.
2. Kasote DM, Katyare SS, Hegde MV, Bae H. Significance of antioxidant potential of plants and its relevance to therapeutic applications. Int J Biol Sci. 2015; 11(8):984-991.
3. Barman NR, Kar PK, Hazam PK, Pal HS, Kumar A, Bhattacharya S, Haldar PK. Cardioprotective effect of *Urtica parviflora* leaf extract against doxorubicin-induced cardiotoxicity in rats. Chinese J Nat Med. 2013; 11(1):38-42.
4. Nohl H, Gille L, Staniek K. The exogenous NADH dehydrogenase of heart mitochondria is the key enzyme responsible for selective cardiotoxicity of anthracyclines. Z Naturforsch C. 1998; 53(3-4):279-285.
5. Yesair DW, Schwartzbach E, Shuck D, Denine EP, Asbell MA. Comparative pharmacokinetics of daunomycin and adriamycin in several animal species. Cancer Res. 1972; 32(6):1177-1183.
6. Rashid S, Ali N, Nafees S, Ahmad ST, Arjumand W, Hasan SK, Sultana S. Alleviation of doxorubicin-induced nephrotoxicity and hepatotoxicity by chrysin in Wistar rats. Toxicol Mech Methods. 2013; 23(5):337-345.
7. Mohan KM, Wolfe CD, Rudd AG, Heuschmann PU, Kolominsky-Rabas PL, Greive AP. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke. 2011; 42(5):1489-1494.
8. Yilmaz S, Atesasihan A, Sahna I, Karahan I, Ozer S. Protective effect of lycopene on adriamycin-induced nephrotoxicity and nephrotoxicity. Toxicology. 2006; 218:164-171.
9. Afroz R, Tanvir EM, Karim N, Hossain MS, Alam N, Gan SH, Khalil MI. Sundarban honey confers protection against isoproterenol-induced myocardial infarction in Wistar rats. Biomed Res Int. 2016; 2016:1-10.
10. Burkhill HM. The Useful Plants of West Tropical Africa, vol. 1. Royal Botanic Gardens, Kew, 1985.
11. Lawal U, Ibrahim H, Agunw A, Abdulahi Y. Anti-inflammatory and analgesic activity of water extract from *Ipomoea asarifolia* Desr (Convolvulaceae). Afr J Biotechnol. 2010; 9(51):8877-8880.
12. Farida T, Salawu OA, Tijani AY, Ejiofor JI. Pharmacological evaluation of *Ipomoea asarifolia* (Desr.) against carbon-tetrachloride-induced hepatotoxicity in rats. J Ethnopharmacol. 2012; 142(3):642-646.
13. Atawodi SE, Onalapo GS. Comparative in vitro antioxidant potential of different parts of *Ipomoea asarifolia*, Roemer and Schultes, *Guiera senegalensis*, J.F. Gmel and *Anisopus mannya* N.E. Brown. Brazil J Pharm Sci. 2010; 46:245-250.
14. Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Guide for the Care and Use of Laboratory Animals, 8th ed. National Academy of Sciences, National Academies Press, Washington DC, USA, 2011.
15. Edeoga HO, Okwu DE, Mbaebie BO. Phytochemical constituents of some Nigerian medicinal plants. Afr J Biotechnol. 2005; 4(7):685-688.
16. Sofoowara A. Medicinal Plants and Traditional Medicine in Africa. Spectrum Books Ltd., Ibadan, Nigeria. 1993; p. 289.
17. Trease GE, Evans WC. Drugs of biological origin. In: Pharmacognosy, 12th ed. United Kingdom Balliere Tindall. 1989; pp. 390-540.
18. Randhawa MA. Calculation of LD₅₀ values from the method of Miller and Tainter, 1944. J Ayub Med Coll Abbottabad. 2009; 21(3):184-185.
19. Hussain Saik A, Rasool SN, Abdul Kareem M, Krushna GS, Akhtar PM, Devi KL. Maslinic acid protects against isoproterenol-induced cardiotoxicity in albino Wistar rats. J Med Food. 2012; 15(8):741-746.
20. Akindele AJ, Iyamu EA, Dutt P, Satti NK, Adeyemi OO. Ameliorative effect of hydroethanolic leaf extract of *Byrocarpus coccinus* in alcohol- and sucrose-induced hypertension in rats. J Tradit Complement Med. 2014; 4(3):177-188.
21. Useh IF, Akpan EJ, Eitim EO, Farombi EO. Antioxidant actions of dried flower extracts of *Hibiscus sabdariffa* L. on sodium arsenite-induced oxidative stress in rats. Pak J Nutr. 2005; 4:135-141.
22. Wu EY, Smith MT, Bellomo G, Di Monte D. Relationships between the mitochondrial transmembrane potential, ATP concentration, and cytotoxicity in isolated rat hepatocytes. Arch Biochem Biophys. 1990; 282(2):358-365.
23. Ahmed KK, Rana AC, Dixin VK. Effect of *Calotropis procera* latex on isoproterenol induced myocardial infarction in albino rats. Phytomedicine. 2004; 11(4):327-330.
24. Swamy BP, Vikram P, Dixin S, Ahmed HU, Kumar A. Meta-analysis of grain yield QTL identified during agricultural drought in grasses showed consensus. BMC Genomics. 2011; 12:319.
25. Chenmmu A and Saleem MT. Antioxidant, lipid lowering, and membrane stabilization effect of sesamol against doxorubicin-induced cardiomyopathy in experimental rats. Biomed Res Int. 2013; 2013:1-5.
26. Palani S, Raja S, Praveen Kumar R, Soumya Jayakumar B, Senthil K. Therapeutic efficacy of *Pimpinella iriapatiensis* (Apiaceae) on acetaminophen induced nephrotoxicity and oxidative stress in male albino rats. Int J Pharm Tech Res. 2009; 1(3):925-934.
27. Stanely Mainzen Prince P, Karthick M. Preventive effect of rutin on lipids, lipoproteins, and ATPases in normal and isoproterenol-induced myocardial infarction in rats. J Biochem Mol Toxicol. 2007; 21(1):1-6.
28. Devika PT, Stanely Mainzen Prince P. Protective effect of (-) epigallocatechin-gallate (EGCG) on lipid peroxide metabolism in isoproterenol induced myocardial infarction in male Wistar rats: a histopathological study. Biomed Pharmacother. 2008; 62(10):701-708.
29. Ozmen A, Canbek M, Senturk H, Bayramoglu G, Uyanoglu M. Possible protective effects of gallic acid against hepatic ischemia reperfusion injury in rats. Sputala DD. 2012; 2(2):101-106.
30. Sohi KK, Mittal N, Hundal MK, Khudruja KL. Gallic acid, an antioxidant, exhibits antiapoptotic potential in normal human lymphocytes: A Bcl-2 independent mechanism. J Nutr Sci Vitaminol. (Tokyo). 2003; 49(4):221-227.
31. Taheri E, Djalali M, Saedisomeolia A, Moghadam AM, Djazayeri A, Qorbani M. The relationship between the activites of antioxidant enzymes in red blood cells and body mass index in Iranian type 2 diabetes and healthy subjects. J Diabetes Metab Disord. 2012; 11(1):3. doi: 10.1186/2251-6581-11-3.

32. Saad SY, Najjar TA, Alashari M. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration. J Biochem Mol Toxicol. 2012; 18(2):78-86.

33. Gille L, Nohl H. Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity. Free Radic Biol Med. 1997; 23(5):775-782.

34. Shaik AH, Rasool SN, Vikram Kumar Reddy A, Abdul Kareem M, Saayi Krishna G, Lakshmi Devi K. Cardioprotective effect of HPLC standardized ethanolic extract of *Terminalia pallida* fruits against isoproterenol-induced myocardial infarction in albino rats. J Ethnopharmacol. 2012; 141(1):33-40.

35. Kumar SHS, Anandan R. Biochemical studies on the cardioprotective effect of glutamine on tissue antioxidant defense system in isoprenaline-induced myocardial infarction in rats. J Clin Biochem Nutr. 2007; 40(1):49-55.

36. Tan PV, Mezui C, Enow-Orock G, Njikam N, Dino T, Bitolog P. Teratogenic effects, acute and subchronic toxicity of the leaf aqueous extract of *Ocimum suave* Wild (Lamiaceae) in rats. J Ethnopharmacol. 2008; 115:232-237.

37. Hayes ML. Guidelines for acute oral toxicity testing. Principles and Methods of Toxicity, 2nd ed. Raven Press Ltd., New York. 1989; p.185.

38. Akindele AJ, Unachukwu EG, Osiagwu DD. 90 Days toxicological assessment of hydroethanolic leaf extract of *Ipomoea asarifolia* (Desr.) Roem. and Schult. (Convolvulaceae) in rats. J Ethnopharmacol. 2015; 174:582-594.

39. Arts IC, Hollman PC. Polyphenols and disease risk in epidemiologic studies. Am J Clin Nutr. 2005; 81(1 Suppl):317S-325S.

40. Foltz CJ, Fox JG, Yan L, Shames B. Evaluation of various oral antimicrobial formulations for eradication of *Helicobacter hepaticus*. Lab Anim Sci. 1996;46(2):193-197.